https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-04 / Hum Vaccin Immunother 2013 Jun;9(6):1217-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-04 / Hum Vaccin Immunother 2013 Jun;9(6):1217-272013-03-04 00:00:002019-02-15 08:48:05Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-01 / Oncoimmunology 2013 Mar;2(3):e23401
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-01 / Oncoimmunology 2013 Mar;2(3):e234012013-03-01 00:00:002019-02-15 08:47:41The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-5042013-02-15 00:00:002019-02-15 08:39:50Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-722013-02-01 00:00:002024-08-26 09:28:16Current status of immunotherapy for the treatment of biliary tract cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / Immunotherapy 2013 Feb;5(2):155-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / Immunotherapy 2013 Feb;5(2):155-672013-02-01 00:00:002019-02-15 08:46:29Vaccine strategies for glioblastoma: progress and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / J. Immunother. 2013 Feb;36(2):152-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / J. Immunother. 2013 Feb;36(2):152-72013-02-01 00:00:002019-02-15 08:46:30Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-01 / Oncoimmunology 2013 Jan;2(1):e22664
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-01 / Oncoimmunology 2013 Jan;2(1):e226642013-01-01 00:00:002020-02-05 10:32:57Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-27 / BMC Cancer 2012 Dec;12:623
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-27 / BMC Cancer 2012 Dec;12:6232012-12-27 00:00:002019-02-15 08:46:31α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-15 / Cancer Immunol. Immunother. 2013 Apr;62(4):761-722012-12-15 00:00:002019-02-15 08:49:50The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-01 / Clin. Exp. Immunol. 2012 Dec;170(3):291-92012-12-01 00:00:002019-02-15 08:48:38Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma
